RDUS - Radius Health, Inc.

NasdaqGM - NasdaqGM Delayed price. Currency in USD
37.91
-0.66 (-1.71%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close38.57
Open38.67
Bid30.15 x 100
Ask36.85 x 100
Day's range37.50 - 39.13
52-week range24.66 - 49.16
Volume384,256
Avg. volume882,819
Market cap1.69B
Beta1.49
PE ratio (TTM)N/A
EPS (TTM)-5.43
Earnings date4 May 2017 - 8 May 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est51.00
Trade prices are not sourced from all markets
  • Taking Stock of Radius Health’s Financial Performance
    Market Realist23 days ago

    Taking Stock of Radius Health’s Financial Performance

    Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue. For 2017 and 2018, Radius Health is expected to post revenue of $23 million and $97.7 million, respectively. Array Biopharma (ARRY) is expected to report revenue of $108 million in 2018.

  • A Strong Pipeline of Drugs Bodes Well for Radius Health
    Market Realist24 days ago

    A Strong Pipeline of Drugs Bodes Well for Radius Health

    The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis. Another candidate is the investigational drug elacestrant (or RAD1901), which is a selective estrogen receptor degrader for the treatment of hormone receptor-positive breast cancer and the treatment of vasometer symptoms in postmenopausal women. The pipeline also includes the investigational drug RAD140, a nonsteroidal selective androgen receptor modulator, for its potential use in treating hormone receptor-positive breast cancer.

  • Analysts’ Ratings for Radius Health and Its Peers in January
    Market Realist24 days ago

    Analysts’ Ratings for Radius Health and Its Peers in January

    Radius Health (RDUS) is a biopharmaceutical company that has recently turned into a commercial stage healthcare company. Of the seven analysts covering Radius Health in January 2018, three have given the stock “buy” or higher ratings, while four have given it “hold” ratings. The mean rating for the stock is 2.43, and it has a target price of $47.5.

  • Globe Newswirelast month

    Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 11:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California.

  • Globe Newswire2 months ago

    Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications

    Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) announced today that Elhan Webb has joined the Company as Head of Investor Relations and External Communications. “We are very fortunate to have someone of Elhan’s caliber to drive our Investor Relations strategy during a pivotal time in the evolution of Radius,” said Jesper Høiland, President and Chief Executive Officer of Radius Health. Ms. Webb is a CFA® charterholder and joins Radius from Genfit Corporation where she was Vice President and Head of Investor Relations.

  • Radius Health to Get Third Day-180 List of Outstanding Issues
    Zacks2 months ago

    Radius Health to Get Third Day-180 List of Outstanding Issues

    Radius Health (RDUS) will get a third Day-180 List of Outstanding Issues from the CHMP for its marketing authorisation application of abaloparatide-SC leading to a further delay in tentative approval.

  • What Happened in the Stock Market Today
    Motley Fool2 months ago

    What Happened in the Stock Market Today

    On a day the indexes closed at record highs, shares of ForeScout soared on strong revenue growth, and Radius Health jumped following encouraging drug trial results.

  • Here's Why Radius Health Is Rising Today
    Motley Fool2 months ago

    Here's Why Radius Health Is Rising Today

    Traders cheer after the company presents encouraging clinical data at a medical conference.

  • Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus
    Zacks4 months ago

    Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus

    Radius Health (RDUS) reported a wider-than-expected loss in third-quarter as expenses grew significantly for the commercialization of Tymlos.

  • Will Radius Health (RDUS) Disappoint This Earnings Season?
    Zacks4 months ago

    Will Radius Health (RDUS) Disappoint This Earnings Season?

    Radius Health (RDUS) has a disappointing track record and we expect the trend to continue when it reports third-quarter results on Nov 2.

  • Radius (RDUS) Enrols First Patient in Breast Cancer Study
    Zacks5 months ago

    Radius (RDUS) Enrols First Patient in Breast Cancer Study

    Radius Health, Inc. (RDUS) announced that the first patient has been enroled in the phase I study on breast cancer candidate RAD140.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes